



Law Project for Psychiatric Rights (PsychRights) • Public Interest Law Firm • Mission: Mount Strategic Litigation Campaign Against Forced Psychiatric Drugging and Electroshock. • Drugging of Children & Youth a Priority





Civil Rights Violations Under 42 U.S.C. §1983 Off-Label Prescribing Constituting Medicaid Fraud FDA Petitions to Withdraw Pediatric Drug Approvals



Most Drugging of Children & Youth in State Custody Unconstitutional

 State obligated to protect children & youth in custody from harm.

Deshaney v. Winnebago County, 489 U.S. 189, 109 S.Ct. 998 (1989):

"[W]hen the State by the affirmative exercise of its power so restrains an individual's liberty that it renders him unable to care for himself, and at the same time fails to provide for his basic human needs-e.g., food, clothing, shelter, medical care, and reasonable safety-it transgresses the substantive limits on state action set by the Eighth Amendment and the Due Process Clause."

M.D. v. Abbott


152 F.Supp.3d 684 (SD Tex. 2015)

- State custody of a child creates a "special relationship" that triggers substantive due process protections.
- Foster children have a Fourteenth Amendment substantive due process right to be free from an unreasonable risk of harm caused by the State.
- State has duty to keep foster children free from an unreasonable risk of harm.
- Don't have to wait for harm to occur
- Includes psychological as well as physical harm.

Payment of Off-Label Prescriptions Restricted Under Medicaid



- Medicaid reimbursement prohibited for outpatient drug prescriptions except for "medically accepted indications," which means indications approved by the Food and Drug Administration (FDA) or supported in at least one of the following compendia:
 - American Hospital Formulary Service Drug Information,
 - United States Pharmacopeia-Drug Information (or its successor publications), or
 - DRUGDEX Information System.



	The Law Project for Psych	iatric Rights (Psych	Rights	
Drug	Indication (diagnosis)	FDA Approval	DRUGDEX Support for Off-Label Use	DRUGDEX Recommendation Level
Key:	White Background: Medically Accepte	ed Indication		
	Orange Background: Pediatric Indicat	ion cited, but not supp		X
	Red Background No Pediatric FDA A	prioval or DRUGDEX o	italion	-
Abilify (Aripipra	role) - Antiprychotic			
	Autistic disorder-Psychomotor agitation	Yes (6-17)		
	Bipolar I Disorder - Adjunctive therapy with lithium or valproate for Agute Mario or Mixed Episodes	Yes (for 10 yrs old and up)		
	Bipolar I Disorder, monotherapy, Manic or Mixed Episodes	Yes (for 10-17 years old re acute therapy)		
	Schizophrenia	Yes (for 13-17 years old)		
Adderall (ample	stamine destroamphetamine) - Central Nervous System Ages	et; CNS Stiendart		
	Attention Deficit Hyperactivity Disorder (ADHD)	Yes (for 3 years old and up ne: [immediate-release] and 6 years old and up re: [extended-release] drug		
97	Narcolepsy	Yes (for 6 years old and up (immediate release only)		
Ambien output	nc) - madratinavia Elypoota			
	Insomna, Short-term treatment	140		Class III
		and Nameson Francisco Assent		Section 1
Anafranil (clos	nipramine) - Antidepressunt; Antidepressunt, Tricyclic; Cent			
Anafranil (close	 Obsessive-Compulsive Disorder 	Yes (for 10 years and up)		

False Claims Act (31 U.S.C §3729, et seq.) • Civil War Era Statute to Address Rampant Fraud Against Government • Amended in 1986, 2009 and 2010 • Allows citizens to bring suit on behalf of the government and share

in recovery if any.


• Called "Relators" (for the King)



Knowingly Defined As: i. Actual knowledge; ii. Deliberate ignorance of the truth or falsity; or iii. Reckless disregard of the truth or falsity No proof of intent to defraud required

31 USC §3729(b)(1)(a)

Penalties • \$5,500 to \$11,000 per false claim, plus treble damages. - Each offending prescription is a false claim 31 USC §3729(a)







Procedural Hurdles



- Public Disclosure Bar
- Particularity
- First to File
- Attorney Required
- Six year statute of limitations

Public Disclosure Bar

(As Amended in 2010)

(4)(A) The court shall dismiss an action or claim under this section, unless opposed by the Government, if substantially the same allegations or transactions as alleged in the action or claim were publicly disclosed—

- (i) in a Federal criminal, civil, or administrative hearing in which the Government or its agent is a party;
- (ii) in a congressional, Government Accountability Office, or other Federal report, hearing, audit, or investigation; or
- (iii) from the news media,

unless the action is brought by the Attorney General or the person bringing the action is an original source of the information.

31 USC §3730(e)(4)(A)

Model Complaint



- Drafted for former foster youth, but anyone with non-public information (i.e., specific prescriptions) can bring.
 - Used in ex rel. Watson v. King-Vassel

A Tale of Two Cases

PsychRights v. Matsutani (9th Cir.)

- Watson v. King-Vassel 7th Cir
- 30+ Defendants
- Ignored Susan Stefan's Excellent Advice Not to Name So many
- 9th Circuit in nonprecedential Disposition: The government knows all about the fraud and doesn't care so why should we? (Public Disclosure Bar)
- Psychiatrists Cause False Claims When Prescribing Off-Label to Medicaid Patient not supported by Any Compendia
- Won in trial court on Public Disclosure Bar
- On Remand, trial court threatened *relator* into folding
- Terrific Precedent, Though

Questions (to be litigated)

- What does "support" in a compendia mean?
 - Drugdex Codes
 - Can a positive report of "3 mentally deficient children & adolescents" receiving Depakote generating a Ilb rating constitute "support?"
 - Is almost all polypharmacy a violation?
- Can Prescribers, Employers & Pharmacies be charged with knowledge?
 - Heckler (Supreme Ct) held charged with knowledge of program requirements
 - -7th Cir.

FDA Drug Approval Criteria



- Drugs are required to be safe & effective for approval. 21 U.S.C. § 355(b)(1)
- Withdrawal of Approval under 21 U.S.C. § 355(e) if:
 - Post approval data show that the drug is unsafe for approved uses
 - New evidence shows lack of substantial evidence drug will have the effect it purports to have under the approved application
 - The application contains any untrue statement of a material fact



